EGFR and non-small cell lung carcinoma: Current Canadian guidelines recommend first-line EGFR-TKI monotherapy for EGFRm metastatic NSCLC patients, based on the results of superior OS, PFS and RR of first-line TKI compared to chemotherapy [18,25].